Review article · 2019 · Open access
Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons
World Psychiatry, 18(2), 208–224 · Published 6 May 2019 · DOI 10.1002/wps.20632
In brief
“Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons” is a 2019 review article by Taishiro Kishimoto and 4 co-authors, published in World Psychiatry. OpenAlex counts 146 citations as of 20 November 2026, which puts it in the top 5% of works published in 2019 by citations. It is open access: the full text is free to read at World Psychiatry.
- Citations
- 146
- Most cited in
- 2021 (32)
- Field-weighted impact
- 2.89
- References
- 92
- Authors
- 5
Abstract
Second-generation antipsychotics (SGAs) are recommended for maintenance treatment in schizophrenia. However, comparative long-term effectiveness among SGAs is unclear. Here we provide a systematic review and meta-analysis of randomized trials lasting ≥⃒6 months comparing SGAs head-to-head in schizophrenia and related disorders. The primary outcome was all-cause discontinuation. Secondary outcomes included efficacy and tolerability, i.e., psychopathology, inefficacy-related and intolerability-related discontinuation, relapse, hospitalization, remission, functioning, quality of life, and adverse events. Pooled risk ratio and standardized mean difference were calculated using random-effects models. Across 59 studies (N=45,787), lasting 47.4±32.1 weeks (range 24-186), no consistent superiority of any SGA emerged across efficacy and tolerability outcomes. Regarding all-cause discontinuation, clozapine, olanzapine and risperidone were significantly (p<0.05) superior to several other SGAs, while quetiapine was inferior to several other SGAs. As to psychopathology, clozapine and olanzapine were superior to several other SGAs, while quetiapine and ziprasidone were inferior to several other SGAs. Data for other efficacy outcomes were sparse. Regarding intolerability-related discontinuation, risperidone was superior and clozapine was inferior to several other SGAs. Concerning weight gain, olanzapine was worse than all other compared non-clozapine SGAs, and risperidone was significantly worse than several other SGAs. As to prolactin increase, risperidone and amisulpride were significantly worse than several other SGAs. Regarding parkinsonism, olanzapine was superior to risperidone, without significant differences pertaining to akathisia. Concerning sedation and somnolence, clozapine and quetiapine were significantly worse than some other SGAs. In summary, different long-term SGA efficacy and tolerability patterns emerged. The long-term risk-benefit profiles of specific SGAs need to be tailored to individual patients to optimize maintenance treatment outcomes.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Kishimoto, T., Hagi, K., Nitta, M., Kane, J. M., & Correll, C. U. (2019). Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons. World Psychiatry, 18(2), 208–224. https://doi.org/10.1002/wps.20632
MLA 9
Kishimoto, Taishiro, et al. “Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons.” World Psychiatry, vol. 18, no. 2, 2019, pp. 208–224. https://doi.org/10.1002/wps.20632.
Chicago
Kishimoto, Taishiro, Katsuhiko Hagi, Masahiro Nitta, John Michael Kane, and Christoph Ulrich Correll. 2019. “Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons.” World Psychiatry 18 (2): 208–224. https://doi.org/10.1002/wps.20632.
Harvard
Kishimoto, T. et al. (2019) ‘Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons’, World Psychiatry, 18(2), pp. 208–224. doi:10.1002/wps.20632.
IEEE
T. Kishimoto, K. Hagi, M. Nitta, J. M. Kane, and C. U. Correll, “Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons,” World Psychiatry, vol. 18, no. 2, pp. 208–224, 2019, doi: 10.1002/wps.20632.
BibTeX
@article{kishimoto2019long,
title = {{Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons}},
author = {Kishimoto, Taishiro and Hagi, Katsuhiko and Nitta, Masahiro and Kane, John Michael and Correll, Christoph Ulrich},
journal = {World Psychiatry},
year = {2019},
volume = {18},
number = {2},
pages = {208--224},
doi = {10.1002/wps.20632},
url = {https://doi.org/10.1002/wps.20632}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2019 | 8 | |
| 2020 | 19 | |
| 2021 | 32 | |
| 2022 | 28 | |
| 2023 | 16 | |
| 2024 | 19 | |
| 2025 | 18 | |
| 2026 | 4 |
Its field-weighted citation impact is 2.89: it has been cited 2.89 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- atypical antipsychotics
- schizophrenia
- long-term maintenance therapy
- head-to-head comparison
- clozapine
- olanzapine
- risperidone
- quetiapine
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Kishimoto, T., Hagi, K., Nitta, M., Kane, J. M., & Correll, C. U. (2019). Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons. World Psychiatry, 18(2), 208–224. https://doi.org/10.1002/wps.20632
How many times has this paper been cited?
146 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at World Psychiatry: sign in and open the PDF from this page.
Who wrote this paper?
Taishiro Kishimoto, Katsuhiko Hagi, Masahiro Nitta, John Michael Kane, Christoph Ulrich Correll.
What is the DOI of this paper?
10.1002/wps.20632, permanently at https://doi.org/10.1002/wps.20632. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.